The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of pathological complete response after DCF neoadjuvant chemotherapy followed by surgery on survival in esophageal squamous cell carcinoma: A supplementary analysis of JCOG 1109.
 
Takako Yoshii
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
 
Tomoya Yokota
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Japan Agency for Medical Research and Development; Merck; MSD; Pharmaceuticals and Medical Devices Agency; Rakuten Medical
Research Funding - Abbvie (Inst); Ascent Pharmahealth (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Japan Agency for Medical Research and Development; Kyowa Kirin International (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nanobiotix (Inst); Novartis (Inst); Syneos Health (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Ryunosuke Machida
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Kazuo Koyanagi
Speakers' Bureau - MSD K.K.; Ono Pharmaceutical
 
Takashi Ogata
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Henlius (Inst); Innovent Biologics (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Takeo Fujita
No Relationships to Disclose
 
Tetsuya Abe
No Relationships to Disclose
 
Kazuaki Harada
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Takeshi Toyozumi
Honoraria - Bristol Myers Squibb Foundation; Ono Pharmaceutical
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Satoshi Kamiya
No Relationships to Disclose
 
Shinsuke Maeda
No Relationships to Disclose
 
Kota Kawabata
No Relationships to Disclose
 
Takeo Bamba
No Relationships to Disclose
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical; Syxmex; Syxmex
 
Hiroya Takeuchi
Honoraria - BeiGene; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nihonkayaku; Novartis; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Sysmex; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tanabe Mitsubishi Pharmaceutical (Inst)